Vineeth Sukrithan, MD
Medical Oncology · Columbus, OHNPI 1659788800
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Exelixis Inc. at 38.7% of the total.
Across 39 payments — averaging $722.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$11K
- Lantheus Medical Imaging, Inc.$5K
- GE HealthCare$5K
- Progenics Pharmaceuticals, Inc.$5K
- Boehringer Ingelheim$3K
- Ipsen Biopharmaceuticals, Inc$200
- plus $128 from 1 others
Across 13 payments — averaging $31,948 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$415K
What the payments were for
- Consulting fees$11,11739%
- Speaking & faculty fees$14,07250%
- Travel & lodging$1,9987%
- Food & beverage$9833%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 21 | $10,904 |
| Lantheus Medical Imaging, Inc. | 1 | $4,778 |
| GE HealthCare | 11 | $4,611 |
| Progenics Pharmaceuticals, Inc. | 2 | $4,590 |
| Boehringer Ingelheim | 1 | $2,960 |
| Ipsen Biopharmaceuticals, Inc | 2 | $200 |
| Genentech USA, Inc. | 1 | $128 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,170 in reported general payments places this provider in the 80th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TafinlarDabrafenib Mesylate | 32 | $428,149 |
| MekinistTrametinib Dimethyl Sulfoxide | 33 | $370,431 |
| RetevmoSelpercatinib | 24 | $206,926 |
| CreonLipase/Protease/Amylase | 11 | $18,158 |
| Ondansetron Hcl | 24 | $2,521 |
| Pantoprazole Sodium | 82 | $553 |
| Dexamethasone | 20 | $450 |
| Klor-Con M20Potassium Chloride | 15 | $310 |
| Omeprazole | 12 | $293 |
| Hydroxyzine Hcl | 14 | $127 |
| Spironolactone | 14 | $90 |
| Prednisone | 13 | $57 |
| Furosemide | 11 | $21 |
| Amlodipine Besylate | 19 | $20 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Columbus
- David CarboneColumbus$438K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Timothy BurnsColumbus$64K
- Kai HeColumbus$49K
- Gregory OttersonColumbus$49K
- Sagar SardesaiColumbus$45K
- Asrar AlahmadiColumbus$36K
- John HaysColumbus$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.